請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79128完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 葉秀慧(Shiou-Hwei Yeh) | |
| dc.contributor.author | Yi-An Shih | en |
| dc.contributor.author | 施怡安 | zh_TW |
| dc.date.accessioned | 2021-07-11T15:46:15Z | - |
| dc.date.available | 2025-08-17 | |
| dc.date.copyright | 2020-09-10 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-17 | |
| dc.identifier.citation | 1. Hubbard, S.R. and J.H. Till, Protein tyrosine kinase structure and function. Annual review of biochemistry, 2000. 69(1): p. 373-398. 2. Robinson, D.R., Y.-M. Wu, and S.-F. Lin, The protein tyrosine kinase family of the human genome. Oncogene, 2000. 19(49): p. 5548-5557. 3. Freiss, G. and D. Chalbos, PTPN13/PTPL1: an important regulator of tumor aggressiveness. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2011. 11(1): p. 78-88. 4. Sato, T., et al., FAP-1: a protein tyrosine phosphatase that associates with Fas. Science, 1995. 268(5209): p. 411-415. 5. Ivanov, V.N., et al., FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Molecular and cellular biology, 2003. 23(10): p. 3623-3635. 6. MAEKAWA, K., et al., Association of protein-tyrosine phosphatase PTP-BAS with the transcription-factor-inhibitory protein IκBα through interaction between the PDZ1 domain and ankyrin repeats. Biochemical Journal, 1999. 337(2): p. 179-184. 7. Nakai, Y., S. Irie, and T.A. Sato, Identification of IκBα as a substrate of Fas‐associated phosphatase‐1. European journal of biochemistry, 2000. 267(24): p. 7170-7175. 8. Lai, Y.-J., W.-C. Lin, and F.-T. Lin, PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. Journal of Biological Chemistry, 2007. 282(33): p. 24381-24387. 9. Yeh, S.-H., et al., Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21. 3 in hepatocellular carcinoma. Clinical Cancer Research, 2006. 12(4): p. 1097-1108. 10. Meinhold-Heerlein, I., et al., Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. The American journal of pathology, 2001. 158(4): p. 1335-1344. 11. Bompard, G., et al., Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells. Journal of Biological Chemistry, 2002. 277(49): p. 47861-47869. 12. Yao, H., et al., Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. British journal of cancer, 2004. 91(9): p. 1718-1725. 13. Ungefroren, H., et al., FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. Journal of cell science, 2001. 114(15): p. 2735-2746. 14. Palmer, A., et al., EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Molecular cell, 2002. 9(4): p. 725-737. 15. Kuchay, S., et al., FBXL2-and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI (3) K signalling cascade. Nature cell biology, 2013. 15(5): p. 472-480. 16. Zhu, J., et al., Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. Oncogene, 2008. 27(18): p. 2525-2531. 17. Wang, Y., et al., The tyrosine phosphatase PTPN13/FAP-1 links calpain-2, TBI and tau tyrosine phosphorylation. Scientific reports, 2017. 7(1): p. 1-13. 18. Kou, X., et al., The Fas/Fap-1/Cav-1 complex regulates IL-1RA secretion in mesenchymal stem cells to accelerate wound healing. Science translational medicine, 2018. 10(432). 19. Nakahira, M., et al., Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity, 2007. 26(2): p. 163-176. 20. Wansink, D.G., et al., Mild impairment of motor nerve repair in mice lacking PTP-BL tyrosine phosphatase activity. Physiological genomics, 2004. 19(1): p. 50-60. 21. Lorber, B., et al., Effects of LAR and PTP‐BL phosphatase deficiency on adult mouse retinal cells activated by lens injury. European journal of neuroscience, 2005. 21(9): p. 2375-2383. 22. Röder, P.V., et al., Pancreatic regulation of glucose homeostasis. Experimental molecular medicine, 2016. 48(3): p. e219-e219. 23. Baggio, L.L. and D.J. Drucker, Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007. 132(6): p. 2131-2157. 24. Kim, W. and J.M. Egan, The role of incretins in glucose homeostasis and diabetes treatment. Pharmacological reviews, 2008. 60(4): p. 470-512. 25. Wang, X., et al., Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology, 2001. 142(5): p. 1820-1827. 26. Svendsen, B., et al., Insulin secretion depends on intra-islet glucagon signaling. Cell reports, 2018. 25(5): p. 1127-1134. e2. 27. Finan, B., M.E. Capozzi, and J.E. Campbell, Repositioning glucagon action in the physiology and pharmacology of diabetes. Diabetes, 2020. 69(4): p. 532-541. 28. Hou, J.C., L. Min, and J.E. Pessin, Insulin granule biogenesis, trafficking and exocytosis. Vitamins Hormones, 2009. 80: p. 473-506. 29. Fu, Z., E. R Gilbert, and D. Liu, Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Current diabetes reviews, 2013. 9(1): p. 25-53. 30. Vakilian, M., Y. Tahamtani, and K. Ghaedi, A review on insulin trafficking and exocytosis. Gene, 2019. 706: p. 52-61. 31. Seino, S. and T. Shibasaki, PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. Physiological reviews, 2005. 85(4): p. 1303-1342. 32. Thakur, P., et al., Effects of PKA-mediated phosphorylation of Snapin on synaptic transmission in cultured hippocampal neurons. Journal of Neuroscience, 2004. 24(29): p. 6476-6481. 33. Holz, G.G., Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic β-cell. Diabetes, 2004. 53(1): p. 5-13. 34. Fletcher, D.A. and R.D. Mullins, Cell mechanics and the cytoskeleton. Nature, 2010. 463(7280): p. 485-492. 35. Kong, X., et al., Glucagon-like peptide 1 stimulates insulin secretion via inhibiting RhoA/ROCK signaling and disassembling glucotoxicity-induced stress fibers. Endocrinology, 2014. 155(12): p. 4676-4685. 36. Riento, K. and A.J. Ridley, Rocks: multifunctional kinases in cell behaviour. Nature reviews Molecular cell biology, 2003. 4(6): p. 446-456. 37. Møller, L.L.V., A. Klip, and L. Sylow, Rho GTPases—Emerging Regulators of Glucose Homeostasis and Metabolic Health. Cells, 2019. 8(5): p. 434. 38. Bernstein, B.W. and J.R. Bamburg, ADF/cofilin: a functional node in cell biology. Trends in cell biology, 2010. 20(4): p. 187-195. 39. Spiering, D. and L. Hodgson, Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell adhesion migration, 2011. 5(2): p. 170-180. 40. Thurmond, D.C., et al., Glucose-stimulated insulin secretion is coupled to the interaction of actin with the t-SNARE (target membrane soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein) complex. Molecular endocrinology, 2003. 17(4): p. 732-742. 41. Li, D.-S., et al., A protocol for islet isolation from mouse pancreas. Nature protocols, 2009. 4(11): p. 1649-1652. 42. Phelps, E.A., et al., Advances in pancreatic islet monolayer culture on glass surfaces enable super-resolution microscopy and insights into beta cell ciliogenesis and proliferation. Scientific reports, 2017. 7: p. 45961. 43. Wang, Z. and D.C. Thurmond, Mechanisms of biphasic insulin-granule exocytosis–roles of the cytoskeleton, small GTPases and SNARE proteins. Journal of cell science, 2009. 122(7): p. 893-903. 44. Alves‐Bezerra, M. and D.E. Cohen, Triglyceride metabolism in the liver. Comprehensive Physiology, 2011. 8(1): p. 1-22. 45. Gerich, J.E. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. in Mayo Clinic Proceedings. 2003. Elsevier. 46. Gerich, J.E., Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes, 2002. 51(suppl 1): p. S117-S121. 47. BRUNZELL, J.D., et al., Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. The Journal of Clinical Endocrinology Metabolism, 1976. 42(2): p. 222-229. 48. Del Prato, S. and A. Tiengo, The importance of first‐phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes/metabolism research and reviews, 2001. 17(3): p. 164-174. 49. Bunt, J.C., et al., Acute insulin response is an independent predictor of type 2 diabetes mellitus in individuals with both normal fasting and 2‐h plasma glucose concentrations. Diabetes/metabolism research and reviews, 2007. 23(4): p. 304-310. 50. Lai, Y.-J., et al., The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration. Molecular and cellular biology, 2010. 30(23): p. 5582-5596. 51. Bai, C.-Y., et al., ZRP-1 controls Rho GTPase-mediated actin reorganization by localizing at cell-matrix and cell-cell adhesions. Journal of cell science, 2007. 120(16): p. 2828-2837. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79128 | - |
| dc.description.abstract | FAP-1為蛋白質酪氨酸磷酸酶家族中的一員,除了能抑制由Fas刺激產生的細胞凋亡,也有研究指出FAP-1可能與抑制腫瘤生長相關。本實驗室先前從荷蘭Dr. Wiljan Hendriks實驗室引進將體內FAP-1具酵素活性的PTP domain剔除 (FAP-1ΔP/ΔP) 的小鼠,經長時間追蹤,發現FAP-1ΔP/ΔP小鼠較Wild-type小鼠體重有顯著的增加。經解剖和組織染色的分析結果指出FAP-1ΔP/ΔP小鼠有較重的白色脂肪,並有脂肪細胞肥大的情形。進一步檢測其進食量和血液生化指標,發現FAP-1ΔP/ΔP小鼠有較高的空腹血糖。為瞭解FAP-1ΔP/ΔP小鼠體內的葡萄糖代謝狀況,我們也同時測量小鼠的空腹胰島素,發現即便FAP-1△P/△P小鼠有較高的空腹血糖,其胰島素數值仍然與野生型小鼠無顯著區別;且經由管餵葡萄糖的葡萄糖耐受性實驗也指出FAP-1ΔP/ΔP小鼠的胰島素釋放量較低。由於經管餵攝入的葡萄糖會透過腸細胞分泌的腸泌素GLP-1引發胰臟β細胞釋放胰島素,因此進一步測量血清中GLP-1的變化,結果指出FAP-1ΔP/ΔP小鼠經管餵葡萄糖仍會分泌GLP-1。進一步以尾靜脈同時注射GLP-1和葡萄糖,發現FAP-1△P/△P小鼠在GLP-1刺激之下無法成功引發胰島素釋放。 根據上述實驗結果,我們因此提出FAP-1可能藉由調控胰臟β細胞中胰島素之釋放,影響小鼠之葡萄糖代謝,導致體重及脂肪增加之表型。由於過去研究指出GLP-1主要會幫助第一階段胰島素的釋放,其中細胞骨架扮演非常重要的角色,因此未來將著重於FAP-1對於胰臟β細胞中細胞骨架的影響進行研究。 | zh_TW |
| dc.description.abstract | FAP-1 is a member of the protein tyrosine phosphatase family, which acts as an inhibitor of Fas-mediated apoptosis. Based on the cell culture based assay, several studies have also indicated FAP-1 to be associated with the inhibition of tumor growth, which still awaits to be validated in vivo. Aiming to study physiological function of FAP-1 in vivo, our lab has delivered a FAP-1 phosphatase-deficient (FAP-1ΔP/ΔP) mouse model from Dr. Wiljan Hendriks’ group. After long-term follow up, we found that FAP-1ΔP/ ΔP mice have significantly higher body weight compared to the wild-type mice, which could be attributed by the hypertrophic adipocytes. Further blood analysis revealed that FAP-1ΔP/ΔP mice have higher fasting blood glucose but equivalent fasting insulin level compared with wild type mice. It suggested a defect of insulin secretion in response to the elevated blood glucose in the FAP-1ΔP/ΔP mice, which indeed has been validated by the oral glucose tolerance test. This study aims to study a possibility that the GLP-1, an incretin hormone released in response to oral glucose gavage to stimulate the secretion of insulin from pancreatic β cells, and its downstream pathway could be defective in FAP-1ΔP/ΔP mice. The GLP-1 level in blood after oral glucose gavage remained normal in the FAP-1ΔP/ΔP mice; however the secretion of insulin after injection of GLP-1 is significantly decreased in the FAP-1△P/△P mice. The results proposed that FAP-1 may function to regulate the secretion of insulin from β cells in response to GLP-1 stimulation, as a mechanism for the increased body weight in FAP-1ΔP/ΔP mice. As documented, GLP-1 mainly induces the first phase of insulin secretion, in which the cytoskeleton plays a very important role. Our ongoing study is thus focused on the function of FAP-1 in regulating the cytoskeleton changes in response to GLP-1 stimulation in primary β cells and in cell culture based assays. Hopefully, the results will help clarify the physiological function of FAP-1 in regulating the glucose metabolism. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T15:46:15Z (GMT). No. of bitstreams: 1 U0001-1708202015452200.pdf: 6646899 bytes, checksum: 6b6902443790bb16ed793bdb752b0816 (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 誌謝 I 摘要 II Abstract III 目錄 V 圖目錄 VIII 第一章 序論 1 1.1 Fas-associated phosphatase-1 (FAP-1) 基因之結構及特性 1 1.2 Fas-associated phosphatase-1 (FAP-1) 基因之功能研究 2 1.3 血液中葡萄糖的恆定與代謝之調控 2 1.4 胰島素於β細胞中的生合成及運送 3 1.5 腸泌素GLP-1調控胰島素釋放之機制 4 1.6 細胞骨架 (cytoskeleton) 在胰島素釋放中扮演的角色 5 1.7 ROCK磷酸酶是調控F-actin解聚之重要調控因子 6 第二章 研究假說及研究策略 8 第三章 材料與方法 9 3.1 實驗小鼠模式 9 3.2 抗體列表 9 3.3 實驗試劑列表 10 3.4 小鼠組織之蛋白質萃取 10 3.5 蛋白質定量分析 10 3.6 小鼠空腹血糖及胰島素測定 11 3.7 小鼠葡萄糖耐受性試驗 11 3.8 小鼠GLP-1注射實驗 11 3.9 小鼠胰島純化分離 (islet isolation) 11 3.10 小鼠正子斷層掃描 (Positron emission tomography, PET) 12 3.11 MIN6細胞株 12 3.12 MIN6細胞株繼代培養 13 3.13 FAP-1缺失之MIN6細胞株建立 13 3.14 葡萄糖刺激胰島素分泌功能分析 (Glucose-stimulated insulin secretion, GSIS) 13 3.15 細胞免疫螢光染色法 (Immunocytochemistry-Immunofluorescence, ICC-IF) 14 第四章 實驗結果 15 4.1 FAP-1△P/△P小鼠自出生2個月起有較重的體重及脂肪組織 15 4.2 FAP-1△P/△P小鼠有脂肪肥大的情形 15 4.3 FAP-1△P/△P小鼠自二至四個月起有較高的空腹血糖與較低的胰島素值 16 4.4 FAP-1△P/△P小鼠有較差的口服葡萄糖促進之胰島素釋放 16 4.5 FAP-1△P/△P小鼠在靜脈葡萄糖耐受試驗中之血糖變化和野生型小鼠無顯著差異 17 4.6 FAP-1△P/△P小鼠在GLP-1刺激之下無法成功引發胰島素釋放 17 4.7 FAP-1△P/△P小鼠有較低的胰島素依賴性葡萄糖吸收與較高的非胰島素依賴性葡萄糖吸收 18 4.8 在MIN6細胞株中建立GLP-1刺激胰島素釋放的模式 18 4.9 MIN6細胞株在GLP-1刺激之下F-actin會隨時間出現解聚的情形 19 4.10 FAP-1缺失MIN6細胞在GLP-1刺激下無法產生F-actin解聚作用 20 4.11 C57BL6/N基因背景之FAP-1△P/△P小鼠的體重自出生3個月起有較重的表型和較高空腹血糖的趨勢 20 第五章 結果討論 22 5.1 小鼠基因背景的影響 22 5.2 FAP-1透過調節血糖影響小鼠體重及油滴堆積之表型 22 5.3 第一階段胰島素釋放缺失是第二型糖尿病的前兆 23 5.4 FAP-1可能參與在GLP-1刺激之β細胞F-actin之解聚作用 24 參考文獻 25 圖附錄 31 | |
| dc.language.iso | zh-TW | |
| dc.subject | FAP-1 | zh_TW |
| dc.subject | F-actin解聚作用 | zh_TW |
| dc.subject | 細胞骨架 | zh_TW |
| dc.subject | 第一階段胰島素釋放 | zh_TW |
| dc.subject | GLP-1 | zh_TW |
| dc.subject | 脂肪細胞肥大 | zh_TW |
| dc.subject | 肥胖 | zh_TW |
| dc.subject | overweight | en |
| dc.subject | GLP-1 | en |
| dc.subject | F-actin depolymerization | en |
| dc.subject | first phase insulin secretion | en |
| dc.subject | hypertrophic adipocytes | en |
| dc.subject | FAP-1 | en |
| dc.subject | cytoskeleton | en |
| dc.title | FAP-1透過調節血糖影響小鼠體重的機制研究 | zh_TW |
| dc.title | Mechanistic study for FAP-1 effect on body weight through regulating blood glucose in mice | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 陳培哲(Pei-Jer Chen),周祖述(Tzuu-Shuh Jou) | |
| dc.subject.keyword | FAP-1,肥胖,脂肪細胞肥大,GLP-1,第一階段胰島素釋放,細胞骨架,F-actin解聚作用, | zh_TW |
| dc.subject.keyword | FAP-1,overweight,hypertrophic adipocytes,GLP-1,first phase insulin secretion,cytoskeleton,F-actin depolymerization, | en |
| dc.relation.page | 46 | |
| dc.identifier.doi | 10.6342/NTU202003779 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2020-08-17 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| dc.date.embargo-lift | 2025-08-17 | - |
| 顯示於系所單位: | 微生物學科所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1708202015452200.pdf 未授權公開取用 | 6.49 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
